# Evaluate the Safety and Efficacy of Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered With Adjuvant AS01B

> **NCT02458092** · PHASE1 · COMPLETED · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 30 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** Plasmodium falciparum Malaria Protein 010 (FMP010)
- **BIOLOGICAL:** Rabipur

## Key facts

- **NCT ID:** NCT02458092
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-12
- **Final completion:** 2009-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-06-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02458092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02458092, "Evaluate the Safety and Efficacy of Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered With Adjuvant AS01B". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02458092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*